此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Avalglucosidase Alfa French 庞贝病参与者的试验后访问(PTA Avalglucosidase)

2026年9月4日 更新者:Genzyme, a Sanofi Company

一项法国多中心 4 期开放标签扩展研究,该研究针对先前参与过法国阿瓦尔葡萄糖苷酶开发研究的庞贝病患者的长期安全性和有效性

这项长期开放标签安全性和有效性研究旨在跟进,并为法国已完成研究 EFC14028、LTS13769 或 ACT14132 的庞贝病患者提供使用阿瓦尔葡萄糖苷酶 alfa 进行酶替代疗法 (ERT) 的试验后访问,从市场授权到法国阿瓦尔葡萄糖苷酶 alfa 报销或到 2023 年 5 月,以先到者为准。

- 研究访问频率:每 2 周一次

研究概览

详细说明

疗程约16个月

研究类型

介入性

注册 (实际的)

17

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Bordeaux、法国、33000
        • Investigational Site Number : 2500004
      • Brest、法国、29609
        • Investigational Site Number : 2500005
      • Clermont-Ferrand、法国、63000
        • Investigational Site Number : 2500008
      • Lille、法国、59037
        • Investigational Site Number : 2500009
      • Lyon、法国、69003
        • Investigational Site Number : 2500003
      • Marseille、法国、13385
        • Investigational Site Number : 2500001
      • Nantes、法国、44093
        • Investigational Site Number : 2500006
      • Nice、法国、06200
        • Investigational Site Number : 2500007
      • Paris、法国、75013
        • Investigational Site Number : 2500002
      • Paris、法国、75015
        • Investigational Site Number : 2500010
      • Tours、法国、37044
        • Investigational Site Number : 2500011

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6个月 及以上 (孩子、成人、年长者)

接受健康志愿者

不

描述

纳入标准:

  • 先前已在法国完成阿瓦尔葡萄糖苷酶 alfa 研究的研究 EFC14028、LTS13769 或 ACT14132 的庞贝病患者。
  • 患者和/或其父母/法定监护人愿意并能够提供签署的知情同意书,如果患者年龄小于 18 岁,则在被认为能够提供同意的情况下愿意提供同意书。
  • 患者(如果患者未满 18 岁,则为患者的法定监护人)必须有能力遵守临床方案。
  • 患者,如果是女性且有生育能力,在入组时必须具有阴性妊娠试验结果 [尿液 β-人绒毛膜促性腺激素 (β-HCG)]。
  • 有生育潜力的性活跃女性患者和男性患者需要按照他们喜欢的和通常的生活方式进行真正的禁欲或使用 2 种可接受的有效避孕方法。

排除标准:

  • 对阿瓦尔葡萄糖苷酶 alfa 的一种赋形剂具有危及生命的超敏反应(过敏反应)的患者。
  • 该患者同时参与另一项试验性治疗的临床研究。
  • 患者患有具有临床意义的器质性疾病(与庞贝病相关的症状除外),包括具有临床意义的心血管、肝胆、肺、神经或肾脏疾病,或其他医学状况、严重并发疾病或情有可原的情况,在研究者的意见,排除参与研究或可能降低生存率。

上述信息并非旨在包含与患者可能参与临床试验相关的所有考虑因素。

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:葡萄糖苷酶α
每隔一周静脉注射一次
药物形式:无菌冻干粉给药途径:静脉内(IV)输注
其他名称:
  • Nexviadyme®

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of participants with adverse events (AE), treatment-emergent adverse events (TEAE), including infusion associated reactions (IAR) and death
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months

次要结果测量

结果测量
措施说明
大体时间
Assessment of six-minute walk test (distance in meters and % predicted value) for late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The primary measurement is the distance in meters walked by the participant on a flat, hard surface in 6 minutes. The distance walked in meters will be recorded and the corresponding percent predicted value will be calculated. The greater the distance (that a participant could walk in 6 minutes), the greater the endurance.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Assessment of quick motor function test (QMFT) for LOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The QMFT is an observer administered test to evaluate changes in motor function. QMFT comprises of 16 items specifically difficult for participants with Pompe disease. Each item is scored separately on a 5-point ordinal scale (ranged from 0 to 4, higher score indicated better outcome). Total QMFT score is obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function), higher score represented better outcome.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Pulmonary function tests (forced vital capacity [FVC] (% predicted), maximum expiratory pressure/maximum inspiratory pressure) in upright and supine positions for LOPD and IOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, also tested in supine position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100.

Maximum Inspiratory Pressure (MIP) is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible.

Maximum Expiratory Pressure (MEP) is a quick and non-invasive test to measure strength of expiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MEP is the greater pressure generated during maximal expiration.

From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: Pompe Disease Symptom Scale (PDSS) for LOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The 24-hour recall PDSS (V1.1) is a self-administered questionnaires specifically designed to capture the symptoms impacts relevant to patients with LOPD. The PDSS includes 12 questions with responses on a scale from 0 (none) to 10 (as bad as I can imagine) The data from PDSS scale will be analyzed separately and as a composite with PDIS scale.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Quality of life evaluation: Pompe Disease Impact Scale (PDIS) for LOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The 24-hour recall PDIS (V1.2) is a self-administered questionnaires specifically designed to capture disease impacts relevant to patients with LOPD. The PDIS includes 15 questions with varying scales implemented depending on question type. The data from PDIS scale will be analyzed separately and as a composite with PDSS scale.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Pompe Pediatric Evaluation of Disability Inventory (Pompe-PEDI) score for IOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
The Pompe-PEDI consists of a Functional Skills Scale and a Caregiver Assistance Scale. Both scales have 3 domains: self-care; mobility; and social function. The Mobility Domain was selected to measure change in mobility secondary to changes in muscle strength. The domain consists of 160 mobility items.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
PedsQL score for IOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

The 23item PedsQL Generic Core Scale encompasses 4 subscales including physical, emotional, school, and social functionings. Scores are transformed to a 0-100 scale, higher scores indicate better HRQOL.

Infant scale will not be used since this is a scale for up to 24 months of age and patients are older now than that.

From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Left Ventricular Mass Index (LVMI) Z-score in IOPD participants
大体时间:From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
Left Ventricular Mass Index (LVMI) equivalent to mean age specific LVMI plus 2 standard deviations.
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Sciences & Operations、Sanofi

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年7月11日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2021年11月16日

首先提交符合 QC 标准的

2021年12月7日

首次发布 (实际的)

2021年12月20日

研究记录更新

最后更新发布 (实际的)

2026年9月9日

上次提交的符合 QC 标准的更新

2026年9月4日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

合格的研究人员可以请求访问患者水平的数据和相关研究文件,包括临床研究报告、带有任何修订的研究方案、空白病例报告表、统计分析计划和数据集规范。 患者层面的数据将被匿名化,研究文件将被编辑以保护试验参与者的隐私。 有关赛诺菲数据共享标准、合格研究和请求访问流程的更多详细信息,请访问:https://vivli.org

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅